Skip to main content

Table 2 Comparison of clinical features of low- and elevated-GMAb sarcoidosis patients

From: Clinical significance of serum anti-granulocyte–macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis

Characteristics

Low-GMAb (n = 87)

Elevated-GMAb (n = 5)

p-value

Age, years

58 [38, 70]

60 [46, 64]

0.849

Male, n

37 [42.5]

2 [40]

1.000

BAL Ly, %

27.6 [19, 40.8]

51.5 [33.6, 71.6]

0.073

BAL CD4/CD8

7.1 [0.82, 7.83]

7.1 [3.8, 8.2]

0.723

LDH, U/L

185 [159–205]

368 [321–414]

0.035

KL-6, U/mL

352 [242, 581]

2318 [871, 9608]

0.003

SP-D, ng/mL

64 [33, 115.7]

244 [80, 882]

0.022

SP-A, ng/mL

31.2 [24.6, 47.5]

47.2 [21.2, 135]

0.475

CEA, ng/mL

2.2 [1.4–3.1]

5.2 [1.9–8.5]

0.444

CYFRA, ng/mL

1.9 [1.2–2.8]

8.1 [5.4–10.7]

0.090

ACE, U/L

21.8 [16.8, 28.3]

31.3 [17.5, 40.8]

0.146

sIL-2R, U/mL

812 [522, 1380]

954 [608, 2011]

0.518

%FVC, %

101.3 [83.8, 114.4]

81.1 [76.2, 110]

0.406

%DLco, %

79.5 [63.8, 97.3]

53.5 [34.7, 103]

0.334

Extra pulmonary lesions, n

47 [54.0]

4 [80]

0.376

 Eye, n

28 [32.2]

3 [60]

 

 Skin, n

6 [6.9]

1 [20]

 

 Heart, n

5 [5.7]

1 [33.3]

 

 Others, n

9 [10.3]

1 [33.3]

 

Use of steroids, n

10 [11.5]

4 [80]

0.002

  1. Data are expressed as the median [IQR] or number [%]
  2. GMAb anti-granulocyte–macrophage colony-stimulating factor autoantibody, BAL bronchial alveolar lavage, Ly lymphocytes, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, SP-D surfactant protein-D, SP-A surfactant protein-A, CEA carcinoembryonic antigen, CYFRA cytokeratin fragment 21-1, ACE angiotensin-converting enzyme, sIL-2R soluble interleukin-2 receptor, %FVC percent predicted forced vital capacity, %DLco percent predicted carbon monoxide diffusing capacity